



**Suppl. Figure 1. H-Leu-Leu-OMe (LLME), staurosporine and histone methyltransferase inhibitors reduce the viability of HMC-1 mast cell leukemia cells.** (A) HMC-1 cells ( $0.5 \times 10^6$  cells/ml) were either left untreated or treated with LLME, Staurosporine, UNC-0636 (histone methyltransferase inhibitor) or UNC-1999 (histone methyltransferase inhibitor) at the indicated concentrations and time periods. Cell viability was then quantified using the CellTiter-Blue Cell Viability Assay. (B) HMC-1 subjected to LLME, Staurosporine, UNC-0636 or UNC-1999 for 24 hours were analyzed by flow cytometry for Annexin V/Draq7 positivity. Data are representative of at least two independent experiments and are given as mean values  $\pm$ SEM ( $n = 3$ ). \*  $p \leq 0.05$ ; \*\*  $p \leq 0.01$ ; \*\*\*  $p \leq 0.001$ ; \*\*\*\*  $p \leq 0.0001$